Stay updated on Aflibercept vs Bevacizumab vs Ranibizumab for DME Clinical Trial

Sign up to get notified when there's something new on the Aflibercept vs Bevacizumab vs Ranibizumab for DME Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Aflibercept vs Bevacizumab vs Ranibizumab for DME Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.0%
    Check dated 2024-06-13T22:38:54.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 on the webpage has recently changed to 8, indicating a shift in the efficacy or safety comparison of intravitreal aflibercept, bevacizumab, and ranibizumab for treating central-involved diabetic macular edema in eyes with specific visual acuity.
    Difference
    0.0%
    Check dated 2024-06-06T14:48:48.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to a detailed description of eligibility criteria for clinical research, including examples such as general health condition and prior treatments. This change provides more specific information about the criteria researchers use to select participants for studies.
    Difference
    24%
    Check dated 2024-05-22T21:22:50.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.5%
    Check dated 2024-04-30T22:19:20.000Z thumbnail image

Stay in the know with updates to Aflibercept vs Bevacizumab vs Ranibizumab for DME Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Aflibercept vs Bevacizumab vs Ranibizumab for DME Clinical Trial page.